After completing pre-clinical studies on its new Zika vaccine candidate Zikavac, Hyderabad, India-based Bharat Biotech announced that the company is now seeking the approval of the government to begin Phase-1 trials where the inactivated vaccine candidate will be tested on 100 people, reports BioSpectrum. 
India has no known cases of the virus so far, but it is widely prevalent in Southeast Asian countries. The company said it’s in touch with the World Health Organization with whom it shares details about the vaccine’s development.
